AURA

Conviction 71HealthcareScan · Mon, Aug 10, 2026

AURA$7.70-3.69%

ResistanceSupportVol 14Insider sell

Vol MA14 476.96K

May 11May 28Jun 16Jul 6Jul 23Aug 10

Aura Biosciences, Inc.BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)www.aurabiosciences.com ↗

Price7.70

Change-3.69%

Gap-0.81%

Rel volume4.62×

Avg volume454.44K

Avg $ vol3.3M

SMA 207.16

SMA 506.95

SMA 2006.41

Price vs 50+10.73%

Price vs 200+19.97%

MA stackbullish

50/200 cross—

Supertrendup · 6.88

RSI (14)61

MACD hist0.08

MACD cross—

Stoch %K / %D75 / 91

ADX (14)11

+DI / −DI25 / 15

RSI divergence—

MACD divergenceBearish

ATR %+4.50%

ADR %3.99%

52w high8.90

52w low4.97

From 52w high-13.54%

Above 52w low+54.83%

New 52w highNo

SqueezeOff

Bollinger width16.21%

%B0.96

Donchian pos76.36%

Donchian high8.00

Donchian low6.71

AVWAP (52w high)7.42

vs AVWAP high+3.69%

AVWAP (52w low)7.11

vs AVWAP low+8.30%

OBV trendFlat

Chaikin MF (20)0.12

Today vs 20d4.62×

Avg vol (14d)476.96K

Avg vol (20d)454.44K

Avg $ vol (20d)3.3M

Market cap795.56M

RS 3m (vs SPY)-8.26%

RS 6m (vs SPY)+34.95%

RS line new highNo

Trend template7/8

Technical rank85.8

1 week+9.30%

1 month+12.50%

3 months-8.39%

6 months+37.41%

1 year+17.48%

YTD+45.19%

P/E-7.49

P/B7.42

P/S—

P/FCF-9.34

EPS-1.76

Div yield—

ROE-99.02%

ROA-77.13%

Debt/Eq—

Current7.09

EV/EBITDA—

Gross margin—

Net margin—

Rev growth—

EPS growth-22.17%

Price target—

Target upside—

Analyst rating—

Institutional—

Ent. value710.77M

Revenue—

Net income-33.69M

Gross profit—

Free cash flow-85.19M

IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

ExchangeNasdaq

Shares out103.39M

Employees113

ListedFri, Oct 29, 2021

Free float44.24M

Float %68.9%

Short interest5.61M

Days to cover8.1d

Short volume50.0%

Squeeze score72 / 100

Next earnings—

EPS forecast—

Last EPS vs est—

Last surprise—

Setup gradeB

Conviction71 / 100

Pattern quality—

Tech rank85.8 / 100

Group rank86 / 100 · Leading

Status laneNo active setup

Setup direction—

Pattern family

Resistance7.61

Support6.35

Days since event—

Candle confirm—

News sentiment—

Financials as of Tue, Mar 31, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in AURA

All disclosures →

No recent disclosed trades by Congress in AURA. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in AURA · 5 buys · 4 sells

Insider	Side	Shares	Value	Traded	Filed
Bender Jeremy Director · Common Stock · 2026-07-07	Grant	30K	—	2026-07-07	2026-07-08
Bender Jeremy Director · Stock Option (Right to Buy) · 2026-07-07	Grant	60K	—	2026-07-07	2026-07-08
Gibney Anthony S See Remarks · Common Stock · 2026-06-16	Sell	12.82K	$82K	2026-06-16	2026-06-16
Holles Natalie C. See Remarks · Stock Option (Right to Buy) · 2026-05-19	Grant	2.17M	$0	2026-05-19	2026-05-19
Holles Natalie C. See Remarks · Common Stock · 2026-05-19	Grant	553.84K	$0	2026-05-19	2026-05-19
Holles Natalie C. See Remarks · Common Stock · 2026-05-19	Grant	600.12K	$0	2026-05-19	2026-05-19
GOEL DAVID E. 10% owner · Common Stock, par value $0.00001 per share (Common Stock) · 2026-05-07	Sell	6.92M	$39M	2026-05-07	2026-05-11
Matrix Capital Management Company, LP 10% owner · Common Stock, par value $0.00001 per share (Common Stock) · 2026-05-07	Sell	6.92M	$39M	2026-05-07	2026-05-11
Kilroy Conor See Remarks · Common Stock · 2026-04-16	Sell	11.74K	$82K	2026-04-16	2026-04-16

SEC filings

EDGAR filings in AURA · 7 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.